Literature DB >> 7695255

Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium avium.

N Mor1, J Vanderkolk, N Mezo, L Heifets.   

Abstract

The combined effect of clarithromycin and rifabutin against Mycobacterium avium multiplying either within human monocyte-derived macrophages or extracellularly in a liquid medium was additive: both MICs and MBCs were twofold lower for the combination than they were for each drug alone. Prolonged exposure for 4 weeks of M. avium-infected macrophages to combined concentrations that were only twofold greater than the MICs resulted in a 100-fold decrease in the number of viable bacteria, while in the drug-free controls a 100-fold or greater increase in comparison with the initial viable counts took place. Comparison of this effect with the results of the prolonged exposure to each drug alone suggested that under these experimental conditions rifabutin enhanced the antimicrobial activity of clarithromycin against intracellular bacteria. At the same time, inhibition of intracellular growth by a 2-h pulsed exposure of the infected macrophages to the combination of the two drugs was not different from the effect induced by clarithromycin alone. In conclusion, clarithromycin played the major role in the antimicrobial activity of the tested combination, while rifabutin may have enhanced this effect during a prolonged exposure of the intracellular bacteria to these two agents.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7695255      PMCID: PMC188278          DOI: 10.1128/AAC.38.12.2738

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  The in-vitro bactericidal activities of combinations of antimicrobial agents against clinical isolates of Mycobacterium avium-intracellulare.

Authors:  R J Kent; M Bakhtiar; D C Shanson
Journal:  J Antimicrob Chemother       Date:  1992-11       Impact factor: 5.790

2.  Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex.

Authors:  N Rastogi; V Labrousse
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages.

Authors:  N Rastogi; V Labrousse; K S Goh; J P De Sousa
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

4.  MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages.

Authors:  N Mor; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

5.  Inhibition of intracellular growth of Mycobacterium avium by one pulsed exposure of infected macrophages to clarithromycin.

Authors:  N Mor; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

6.  The penetration of rifampicin, pyrazinamide, and pyrazinoic acid into mouse macrophages.

Authors:  G Acocella; N A Carlone; A M Cuffini; G Cavallo
Journal:  Am Rev Respir Dis       Date:  1985-12

7.  Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium.

Authors:  L B Heifets; P J Lindholm-Levy; R D Comstock
Journal:  Am Rev Respir Dis       Date:  1992-04

8.  Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages.

Authors:  J Dhillon; D A Mitchison
Journal:  Am Rev Respir Dis       Date:  1992-01

9.  Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages.

Authors:  N Mor; J Vanderkolk; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

10.  Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods.

Authors:  L B Heifets; M D Iseman; P J Lindholm-Levy; W Kanes
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

View more
  11 in total

Review 1.  Risk-benefit assessment of therapies for Mycobacterium avium complex infections.

Authors:  D E Griffith
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

2.  Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.

Authors:  R Hafner; J Bethel; M Power; B Landry; M Banach; L Mole; H C Standiford; S Follansbee; P Kumar; R Raasch; D Cohn; D Mushatt; G Drusano
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

3.  Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages.

Authors:  N Mor; B Simon; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

4.  The phagosomal environment protects virulent Mycobacterium avium from killing and destruction by clarithromycin.

Authors:  C Fréhel; C Offredo; C de Chastellier
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

5.  Activities of poloxamer CRL-1072 against Mycobacterium avium in macrophage culture and in mice.

Authors:  C Jagannath; M R Emanuele; R L Hunter
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

Review 6.  The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections.

Authors:  G W Amsden; C A Peloquin; S E Berning
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

7.  Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages.

Authors:  N Mor; B Simon; N Mezo; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 8.  Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes.

Authors:  C A Peloquin
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

9.  Pulsed-exposure and postantibiotic leukocyte enhancement effects of amikacin, clarithromycin, clofazimine, and rifampin against intracellular Mycobacterium avium.

Authors:  L Horgen; A Jerome; N Rastogi
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Suspected intestinal tuberculosis might be Crohn's disease.

Authors:  Semiu Eniola Folaranmi; Gautam Mehta; Debasis Datta; Greg Holdstock
Journal:  Case Rep Med       Date:  2010-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.